Brian Do, MD
Retina Specialist · Chevy Chase, MDNPI 1073807681
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $71,246 of the $115,824 with a category attached, or 61.5%. 23 manufacturers reported payments, led by AbbVie at 59.3% of the total. 2025 is the largest year on record at $24,069, more than ten times the $1,019 reported in 2019. Among retina specialist clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 236 payments — averaging $490.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$69K
- Eyepoint US, Inc.$17K
- ANI Pharmaceuticals, Inc.$8K
- Bausch & Lomb Americas Inc.$6K
- Alimera Sciences, Inc.$4K
- Apellis Pharmaceuticals, Inc.$2K
- plus $9K from 17 others
Across 229 payments — averaging $4140.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$507K
- Janssen Research & Development, LLC$267K
- Apellis Pharmaceuticals, Inc.$174K
What the payments were for
- Consulting fees$32,64628%
- Speaking & faculty fees$71,24662%
- Travel & lodging$4,2364%
- Food & beverage$7,6957%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 84 | $68,729 |
| Eyepoint US, Inc. | 28 | $17,105 |
| ANI Pharmaceuticals, Inc. | 6 | $7,798 |
| Bausch & Lomb Americas Inc. | 12 | $6,269 |
| Alimera Sciences, Inc. | 15 | $3,960 |
| Apellis Pharmaceuticals, Inc. | 6 | $2,474 |
| Genentech, Inc. | 6 | $1,915 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $1,741 |
| Ocular Therapeutix, Inc. | 1 | $1,600 |
| Genentech USA, Inc. | 24 | $1,576 |
| Alcon | 10 | $779 |
| Neurotech Pharmaceuticals, Inc. | 3 | $446 |
| Regeneron Healthcare Solutions, Inc. | 13 | $436 |
| Astellas Pharma US Inc | 8 | $278 |
| Biotissue Holdings Inc. | 1 | $137 |
| Kala Pharmaceuticals, Inc. | 1 | $125 |
| Shire North American Group Inc | 1 | $123 |
| Novartis | 5 | $112 |
| Sanofi US Services Inc. | 2 | $106 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Oculus Surgical Inc. | 1 | $18 |
| Astellas Pharma Global Development | 1 | $17 |
| Penumbra, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$64,883
- YUTIQ$19,643
- PURIFIED CORTROPHIN GEL$7,705
- XIPERE$4,339
- VABYSMO$2,640
- Iluvien$2,432
- SUSVIMO$1,908
- SURGICAL MISC$800
- Constellation$525
- Prokera$137
- Syfovre$125
- INVELTYS$125
- XIIDRA$123
- STELLARIS PC$115
- Izervay$100
How this compares
$115,824 in reported general payments places this provider in the 95th percentile of 47 retina specialist providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 29 | $408,796 |
| Prednisolone Acetate | 257 | $12,204 |
| ValacyclovirValacyclovir Hcl | 48 | $4,074 |
| Difluprednate | 37 | $3,203 |
| Ketorolac Tromethamine | 106 | $2,068 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 80 | $1,445 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 24 | $494 |
| Prednisone | 76 | $472 |
| Ofloxacin | 18 | $339 |
| Dorzolamide Hcl | 22 | $263 |
| Brimonidine Tartrate | 19 | $244 |
| Latanoprost | 20 | $157 |
| Timolol Maleate | 33 | $152 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Chevy Chase
- Michael LaiChevy Chase$13K
- Richard GarfinkelChevy Chase$5K
- Gayatri ReillyChevy Chase$2K
- Daniel BerinsteinChevy Chase$1K
- Rohit LakhanpalOwings Mills$168K
- Adam GerstenblithHagerstown$107K
- Aziz KhanifarSilver Spring$83K
- Michael ElmanBaltimore$27K
- Reginald SandersGreenbelt$24K
- Sidney SchechetBaltimore$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.